Skip to search formSkip to main contentSkip to account menu

PBI-1402

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
Abstract 3534: PBI-1402, a first-in-class erythropoiesis regulating agent, possesses differentiation properties and demonstrates synergistic anticancer activity in combination with chemotherapy
Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL Background: PBI-1402 reduces the need for transfusion… 
2011
2011
Abstract 672: PBI-1402, a first-in-class erythropoiesis regulating agent, inhibits tumor growth and metastasis of murine mastocytoma and does not overshoot hemoglobin: Comparison with erythropoietin
BACKGROUND: PBI-1402 reduces the need for transfusion and increases hemoglobin (Hb) level and red blood cell count (RBC) in… 
2008
2008
Gateways to clinical trials.
(-)-Epigallocatechin gallate, (-)-Gossypol; Ad.hIFN-beta, AF-37702, Agatolimod sodium, Agomelatine, Alvocidib hydrochloride, ARC… 
2008
2008
Gateways to clinical trials.
Gateways to Clinical Trials are a guide to the most recent clinical trials in current literature and congresses. The data in the… 
2007
2007
Oral Treatment with PBI-1402 Increases Hemoglobin Level and Red Blood Cell Count: A Novel Approach to Treating Chemotherapy-Induced Anemia.
Background: PBI-1402 is a novel orally active low molecular weight synthetic compound with erythropoiesis stimulating activity… 
2006
2006
PBI-1402: A Low Molecular Weight Synthetic Hematopoietic Growth Stimulant.
PBI-1402 is a non-toxic, well-defined low molecular weight synthetic hematopoietic growth stimulant. PBI-1402 promotes the… 
2006
2006
PBI-1402: A New Candidate for the Treatment of Anemia.
PBI-1402 is an orally active low molecular weight synthetic compound which is currently in a phase Ib/II clinical trial in… 
2006
2006
PBI-1402: A Non-Toxic Immunorestorative Small Molecule for the Treatment of Anemia.
Erythropoiesis is regulated by an intricated network of transcription factors and other molecules that mediate differentiation of… 
2006
2006
Oral Administration of PBI-1402 Significantly Reduces Erythropenia and Accelerates Peripheral Blood Recovery in Myeloablated Mice Post Transplantation.
The goal of this study was to determine the potential of PBI-1402, a compound that was shown to provide radio- and… 
2005
2005
Gateways to clinical trials.
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)